Format

Send to

Choose Destination
J Cereb Blood Flow Metab. 2012 Nov;32(11):2002-11. doi: 10.1038/jcbfm.2012.112. Epub 2012 Jul 25.

A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.

Author information

1
Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.

Abstract

Breast cancer resistance protein (BCRP) is the most abundant multidrug efflux transporter at the human blood-brain barrier (BBB), restricting brain distribution of various drugs. In this study, we developed a positron emission tomography (PET) protocol to visualize Bcrp function at the murine BBB, based on the dual P-glycoprotein (P-gp)/Bcrp substrate radiotracer [(11)C]tariquidar in combination with the Bcrp inhibitor Ko143. To eliminate the contribution of P-gp efflux to [(11)C]tariquidar brain distribution, we studied mice in which P-gp was genetically knocked out (Mdr1a/b((-/-)) mice) or chemically knocked out by pretreatment with cold tariquidar. We found that [(11)C]tariquidar brain uptake increased dose dependently after administration of escalating doses of Ko143, both in Mdr1a/b((-/-)) mice and in tariquidar pretreated wild-type mice. After 15 mg/kg Ko143, the maximum increase in [(11)C]tariquidar brain uptake relative to baseline scans was 6.3-fold in Mdr1a/b((-/-)) mice with a half-maximum effect dose of 4.98 mg/kg and 3.6-fold in tariquidar (8 mg/kg) pretreated wild-type mice, suggesting that the presented protocol is sensitive to visualize a range of different functional Bcrp activities at the murine BBB. We expect that this protocol can be translated to the clinic, because tariquidar can be safely administered to humans at doses that completely inhibit cerebral P-gp.

PMID:
22828996
PMCID:
PMC3493998
DOI:
10.1038/jcbfm.2012.112
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center